Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-PSMA-XT in metastatic prostate cancer
NCT07096128Phase 1Recruiting
- Start
- Aug 2024
- Primary completion
- May 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [177Lu]Lu-PSMA-XT in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 2 years, Dose-limiting toxicity up to 2 years and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
[177Lu]Lu-PSMA-XT
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07096128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096128.